EDMONTON, Alberta — In a move designed to bolster its international supply chain, Aurora Cannabis has acquired Safari Flower Company, an established EU GMP-certified cannabis cultivator and manufacturer, in a deal valued at $26.5 million.
The acquisition provides Aurora with a 59,000-square-foot, purpose-built indoor cultivation and manufacturing facility in Ontario. The addition of this EU GMP-certified footprint is expected to directly complement Aurora's existing operations and provide the incremental capacity required to service high-margin, highly regulated international markets.
Aurora plans to channel the increased manufacturing output to its primary international markets, which include Germany, Australia, Poland, and the UK.
"The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market," said Miguel Martin, Executive Chairman and CEO of Aurora.
Martin emphasized that the company will lean on its established plant science and operational expertise to optimize the newly acquired site. "An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide," he added.
Operational and Financial Impact
From an operational standpoint, Aurora intends to integrate Safari Flower into its broader supply network to realize immediate production efficiencies and improve overall cultivation yields.
The $26.5 million aggregate consideration includes a $15 million cash payment and the issuance of 2,417,180 common shares to the selling shareholder upon closing, alongside a contingent $2 million cash payment based on specific conditions.
Aurora projects that optimizing these manufacturing assets will yield positive Adjusted EBITDA contributions by fiscal year 2027, with continued operational benefits rolling into fiscal year 2028 and beyond.
